Effect of duloxetine hydrochloride combined with tandospirone on anxiety and depression in COPD patients
Objective To explore the clinical effect of duloxetine hydrochloride combined with tandospirone in the treatment of anxiety and depression in patients with chronic obstructive pulmonary disease(COPD).Methods A total of 82 COPD patients with anxiety and depression who were admitted to The People's Hospital of Rugao from March 2017 to September 2022 were enrolled and divided into two groups by random number table,with 41 cases in each group.The control group was given duloxetine hydrochloride(40 mg/d,20 mg each time,bid),and the observation group was given duloxetine hydrochloride(40 mg/d,20 mg each time,bid)and tandospirone(30 mg/d,10 mg each time,tid)for 8 weeks.The clinical efficacy,the degree of anxiety and depression,lung function,neurotransmitter levels,adverse drug reactions,and the safety of therapeutic regimens were evaluated.Results The total effective rate of the observation group was significantly higher than that of the control group(95.12%[39/41]vs 78.05%[32/41],P<0.05).Hamilton depression scale(HAMD)score,Hamilton anxiety scale(HAMA)score,and Pittsburgh sleep quality index(PSQI)were decreased after treatment in both groups,and these scores in the observation group were lower than those in the control group(all P<0.05).After treatment,the levels of nerve growth factor(NGF)and 5-hydroxytryptamine(5-HT)in both groups were increased,and BDNF and 5-HT in the observation group were higher than those in the control group(all P<0.05).The forced expiratory volume in the first second(FEV1)and the ratio of FEV1 to forced vital capacity(FEV)after treatment were higher than those before treatment(P<0.05).There were no significant differences in FEV1 or FEV1/FVC between groups after treatment(P>0.05).The adverse reaction rates of observation group and control group were 24.39%(10/41)and 14.63%(6/41),respectively(P>0.05).Conclusion Duloxetine hydrochloride combined with tandospirone can increase neurotransmitter levels and improve the degree of anxiety and depression in COPD patients.
Duloxetine hydrochlorideTandospironeChronic obstructive pulmonary diseaseAnxiety and depression